U.S. Semiconductors Stock News

NasdaqGS:BMRN
NasdaqGS:BMRNBiotechs

What BioMarin Pharmaceutical (BMRN)'s Voxzogo Trial Stops and Mixed Safety Data Mean For Shareholders

Recently, BioMarin Pharmaceutical discontinued three Phase 2 Voxzogo studies following safety concerns, while simultaneously reporting encouraging clinical and real-world outcomes for the drug in other settings. The company and analysts now suggest that Voxzogo’s safety issues may be limited to specific uses, with BioMarin’s broader outlook increasingly supported by its wider rare-disease portfolio. Now we’ll explore how the Voxzogo safety-driven trial discontinuations, alongside positive...
OTCPK:CMRF
OTCPK:CMRFRetail REITs

CIM Real Estate Finance Trust (OTCPK:CMRF) Revenue Slippage Tests Income-Focused Bullish Narratives

CIM Real Estate Finance Trust (OTCPK:CMRF) has wrapped up FY 2025 with fourth quarter revenue of US$97.9 million and basic EPS of US$0.07, giving investors a clean snapshot of how the year finished. Over recent periods, revenue has shifted from US$121.4 million in Q3 2024 to US$106.2 million in Q4 2024, then to US$106.4 million in Q1 2025, US$107.2 million in Q2 2025, US$104.5 million in Q3 2025 and US$97.9 million in Q4 2025, while quarterly EPS moved from US$0.02 to an interim loss before...
NYSE:COMP
NYSE:COMPReal Estate

Has The Recent Share Price Slide Opened An Opportunity In Compass (COMP)?

This article examines whether Compass at US$6.84 may represent attractive value or a potential value trap by exploring what the current price could be implying about the business. The stock has come under pressure recently, with a 19.2% decline over the last 7 days, 29.8% over 30 days, 34.9% year to date, and 21.6% over the past year, following a very large 3-year gain of 110.5% and a 5-year decline of 63.2%. Recent coverage has highlighted Compass as a real estate platform operating in a...
NasdaqGS:ROKU
NasdaqGS:ROKUEntertainment

Is It Time To Reconsider Roku (ROKU) After Its Recent Share Price Pullback

If you are wondering whether Roku's current share price reflects its true worth, you are not alone; the stock's recent moves have raised fresh questions about what you are really paying for. Roku closed at US$88.23, with returns of a 9.8% decline over 7 days, a 10.3% decline over 30 days and an 18.8% decline year to date, set against a 25.3% gain over 1 year and 34.3% over 3 years, while the 5 year return stands at a 73.1% decline. Recent headlines around Roku have focused on its position in...
NasdaqGS:ATEC
NasdaqGS:ATECMedical Equipment

Is It Time To Reconsider Alphatec Holdings (ATEC) After Its Sharp Share Price Slide

If you are wondering whether Alphatec Holdings at around US$11 is a bargain or a value trap, the key is to look past the headline share price and into how it stacks up on valuation. The stock has seen a 9.5% decline over the last week, a 19.2% decline over the last 30 days, and is down 47.0% year to date, even though the 1 year return sits at 8.5%. These moves sit against a backdrop of ongoing interest in medical equipment companies, with investors weighing up growth potential in specialist...
NYSE:BOX
NYSE:BOXSoftware

How Box (BOX) Buyback Expansion Shapes The Latest Valuation Debate

Box (BOX) has expanded its equity buyback plan, adding US$500 million in authorization to reach US$1.86b and extending the program through September 30, 2027. This move refocuses attention on capital returns. See our latest analysis for Box. At a share price of US$23.32, Box has a 90 day share price return of 23.31% and a one year total shareholder return of 24.43% decline, pointing to fading momentum even as the larger buyback program draws fresh attention from investors. If you are weighing...
NYSE:BMY
NYSE:BMYPharmaceuticals

Is Bristol Myers Squibb (BMY) Price Near US$60 Supported By Cash Flow And Earnings Models

Wondering if Bristol-Myers Squibb at around US$59.73 is a bargain or a value trap? This article walks through the key signals that matter for you as a shareholder or potential investor. The stock is up 4.8% over the last week and 11.7% year to date. However, the 30-day return is a 4.2% decline and the one-year return sits at 2.9%, with a three-year return of a 1.7% decline and a five-year return of 14.4%. Recent attention on large pharmaceutical names, including Bristol-Myers Squibb, has...
NYSE:XPEV
NYSE:XPEVAuto

Is It Time To Reassess XPeng (XPEV) After Recent Share Price Weakness

If you are wondering whether XPeng's share price reflects its real worth, or if the market is mispricing the story, this article walks you through what the numbers are actually saying. XPeng's stock last closed at US$16.72, with returns of an 11.4% decline over 7 days, 4.8% decline over 30 days, 18.2% decline year to date and 19.3% decline over 1 year, set against a 52.0% gain over 3 years and 53.6% decline over 5 years. These mixed returns sit against a backdrop of ongoing headlines about...
NasdaqGS:KLAC
NasdaqGS:KLACSemiconductor

Iran Tensions And Helium Risks Put KLA Supply Chain In Focus

Rising geopolitical tensions linked to the Iran war are raising fresh concerns about semiconductor supply chains. Helium, a key material for chip manufacturing, is in focus as potential disruption risks resurface. KLA Corporation (NasdaqGS:KLAC), a major supplier of process control and metrology tools to chip fabs, sits close to these supply chain fault lines. KLA earns much of its business from equipment and services that depend on stable fab activity and access to advanced materials such...
NYSE:VOYG
NYSE:VOYGAerospace & Defense

Assessing Voyager Technologies (VOYG) Valuation After Earnings And Sharper Focus On Starlab Potential

Voyager Technologies (VOYG) has drawn investor attention after posting annual revenue of US$166.419 million alongside a net loss of US$116.072 million, raising fresh questions about how its defense and space businesses are being valued. See our latest analysis for Voyager Technologies. The recent earnings update has coincided with a 7 day share price return of 21.54% decline and a year to date share price return of 21.06% decline, suggesting momentum has weakened despite earlier optimism...
NYSE:BAH
NYSE:BAHProfessional Services

Is Booz Allen Hamilton (BAH) Pricing Reflect Its DCF Value After Recent Share Weakness

If you are wondering whether Booz Allen Hamilton Holding is attractively priced right now or if the recent share level is hard to justify, this breakdown focuses squarely on what you are getting for the price you pay. The stock last closed at US$78.95, with returns of a 1.2% decline over 7 days, 0.2% over 30 days, and year-to-date and 1-year returns of a 7.0% decline and 22.6% decline. These figures may prompt questions about whether sentiment or valuation has shifted too far. Recent news...
NasdaqCM:MLTX
NasdaqCM:MLTXBiotechs

Assessing MoonLake Immunotherapeutics (MLTX) Valuation After A Premium Price To Book Multiple And Recent Share Moves

MoonLake Immunotherapeutics: recent stock performance snapshot MoonLake Immunotherapeutics (MLTX) has seen mixed trading moves recently, with the stock down 2.3% over the past day and roughly 3.3% over the past month, while showing a gain of about 28% in the past 3 months. See our latest analysis for MoonLake Immunotherapeutics. The current share price of $16.93 sits alongside a 90 day share price return of 28.45% and a year to date share price return of 41.67%. In contrast, the 1 year total...
NYSE:AMTB
NYSE:AMTBBanks

3 Undervalued Small Caps With Insider Action To Watch

Over the last 7 days, the United States market has experienced a 3.5% drop, yet it remains up by 14% over the past year with earnings forecasted to grow by 15% annually. In this fluctuating environment, identifying stocks that are potentially undervalued and have notable insider activity can be key to uncovering promising opportunities in the small-cap sector.
NasdaqGM:VCEL
NasdaqGM:VCELBiotechs

Exploring Three High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 14% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks requires a focus on companies with strong innovation potential and robust financial health that can capitalize on long-term trends despite short-term fluctuations.
NasdaqGS:WLTH
NasdaqGS:WLTHCapital Markets

Three Stocks That Could Be Trading Below Estimated Value In March 2026

The United States market has experienced a 3.5% decline over the past week, yet it remains up by 14% over the last year, with earnings projected to grow by 15% annually. In this context, finding stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on long-term growth prospects amidst fluctuating market conditions.
NasdaqGS:CHEF
NasdaqGS:CHEFConsumer Retailing

Chefs’ Warehouse (CHEF) Valuation Check After Recent Share Price Pullback

Chefs' Warehouse (CHEF) has drawn investor attention after a monthly return of about an 18% decline, contrasting with an 8% gain over the past year, prompting a closer look at its current valuation and fundamentals. See our latest analysis for Chefs' Warehouse. Despite the recent 18% monthly share price return decline and a 5.8% 90 day share price return decline, Chefs' Warehouse still shows an 8.1% 1 year total shareholder return and an 86.1% 5 year total shareholder return, suggesting...
NasdaqGM:BETR
NasdaqGM:BETRDiversified Financial

3 Growth Companies With High Insider Ownership Achieving Up To 97% Earnings Growth

Over the last 7 days, the United States market has experienced a 3.5% drop, yet it has risen by 14% over the past year with earnings projected to grow by 15% annually in the coming years. In this environment, growth companies with high insider ownership can be particularly appealing as they may align management's interests with shareholders and potentially drive significant earnings growth.
NasdaqGM:HERE
NasdaqGM:HERELeisure

3 Promising Penny Stocks With Market Caps Up To $200M

Over the last 7 days, the U.S. market has dropped 3.5%, but it has risen by 14% over the past year, with earnings forecasted to grow annually by 15%. Investing in penny stocks — a term that may feel outdated yet remains relevant — can still provide access to growth opportunities, especially within smaller or newer companies. By focusing on those with robust financials and clear growth potential, investors can uncover valuable opportunities among these lesser-known stocks.
NYSE:ASIC
NYSE:ASICInsurance

US Undiscovered Gems to Explore in March 2026

Over the last 7 days, the United States market has dropped 3.5%, yet it has seen a robust rise of 14% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying stocks with strong fundamentals and growth potential can be key to uncovering undiscovered gems worth exploring in March 2026.
NasdaqGS:PCB
NasdaqGS:PCBBanks

3 Reliable Dividend Stocks Offering Up To 10.6% Yield

Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 14% over the past year with earnings anticipated to grow by 15% annually in the coming years. In this fluctuating environment, dividend stocks that offer substantial yields can provide a reliable income stream and potential stability for investors seeking consistent returns amidst market volatility.